Meaningful Improvement and Worsening in Patients Who Do Not Achieve Low Disease Activity and Switch Therapy to a New Biologic or Targeted Disease-Modifying Antirheumatic Drug: Results From the CorEvitas RA Registry.

Curtis, Jeffrey R; Fiore, Stefano; Ford, Kerri; Janak, Jud C; Chang, Hong; Pappas, Dimitrios A; Blachley, Taylor; Emeanuru, Kelechi; Bykerk, Vivian P

Curtis, Jeffrey R; Fiore, Stefano; Ford, Kerri; Janak, Jud C; Chang, Hong; Pappas, Dimitrios A; Blachley, Taylor; Emeanuru, Kelechi; Bykerk, Vivian P.

Affiliation

Curtis JR; From the University of Alabama at Birmingham, Birmingham, AL.
Fiore S; Sanofi, Bridgewater, NJ.
Ford K; Sanofi, Cambridge.
Janak JC; CorEvitas, LLC, Waltham, MA.
Chang H; CorEvitas, LLC, Waltham, MA.
Blachley T; CorEvitas, LLC, Waltham, MA.
Emeanuru K; CorEvitas, LLC, Waltham, MA.
Bykerk VP; Hospital for Special Surgery, New York, NY.

J Clin Rheumatol ; 29(4): e47-e51, 2023 Jun 01.

Article in En | MEDLINE | ID: mdl-37000177

Subject(s)

Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Humans; Antirheumatic Agents/therapeutic use; Arthritis, Rheumatoid/diagnosis; Arthritis, Rheumatoid/drug therapy; Biological Products/adverse effects; Registries; Treatment Outcome

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Arthritis, Rheumatoid / Biological Products / Antirheumatic Agents Type of study: Diagnostic_studies / Observational_studies Limits: Humans Language: En Journal: J Clin Rheumatol Journal subject: FISIOLOGIA / ORTOPEDIA / REUMATOLOGIA Year: 2023 Document type: Article Affiliation country: Albania

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google